Home
/
ABEONA THERAPEUTICS INC.
/
Financials
/
Quarterly
ABEONA THERAPEUTICS INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ABEONA THERAPEUTICS INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2019
Jun 30, 2019
$0
Aug 9, 2019
Q1
2019
Mar 31, 2019
$0
May 10, 2019
Q3
2018
Sep 30, 2018
$1.71M
Nov 9, 2018
Q2
2019
Jun 30, 2018
$276.0K
Aug 9, 2019
Q1
2019
Mar 31, 2018
$531.0K
May 10, 2019
Q3
2018
Sep 30, 2017
$219.0K
Nov 9, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$400.0K
Nov 12, 2025
Q2
2025
Jun 30, 2025
$400.0K
Aug 14, 2025
Q3
2024
Sep 30, 2023
$3.50M
Nov 14, 2024
Q2
2024
Jun 30, 2023
$3.50M
Aug 12, 2024
Q3
2023
Sep 30, 2022
$1.35M
Nov 13, 2023
Q2
2023
Jun 30, 2022
$1.00M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$346.0K
May 11, 2023
Q3
2021
Sep 30, 2020
$7.00M
Nov 15, 2021
Q3
2019
Sep 30, 2018
$1.71M
Nov 12, 2019
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$2.60M
May 10, 2018
Q3
2017
Sep 30, 2017
$219.0K
Nov 14, 2017
Q2
2017
Jun 30, 2017
$217.0K
Aug 14, 2017
Q1
2018
Mar 31, 2017
$186.0K
May 10, 2018
Q3
2017
Sep 30, 2016
$184.0K
Nov 14, 2017
Q2
2017
Jun 30, 2016
$214.0K
Aug 14, 2017
Q1
2017
Mar 31, 2016
$235.0K
May 15, 2017
Q3
2016
Sep 30, 2015
$285.0K
Nov 14, 2016
Q2
2016
Jun 30, 2015
$282.0K
Aug 15, 2016
Q1
2016
Mar 31, 2015
$258.0K
May 16, 2016
Q3
2015
Sep 30, 2014
$236.0K
Nov 16, 2015
Q2
2015
Jun 30, 2014
$247.0K
Aug 14, 2015
Q1
2015
Mar 31, 2014
$208.0K
May 14, 2015
Q3
2014
Sep 30, 2013
$189.0K
Nov 14, 2014
Q2
2014
Jun 30, 2013
$467.0K
Aug 14, 2014
Q1
2014
Mar 31, 2013
$1.22M
May 12, 2014
Q3
2013
Sep 30, 2012
$871.0K
Nov 14, 2013
Q2
2013
Jun 30, 2012
$690.0K
Aug 14, 2013
Q1
2013
Mar 31, 2012
$1.84M
May 15, 2013
Q3
2012
Sep 30, 2011
$1.04M
Nov 14, 2012
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($5.16M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
$108.83M
Aug 14, 2025
Q1
2025
Mar 31, 2025
($12.03M)
May 15, 2025
Q3
2025
Sep 30, 2024
($30.27M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
$7.41M
Aug 14, 2025
Q1
2025
Mar 31, 2024
($31.58M)
May 15, 2025
Q3
2024
Sep 30, 2023
($11.84M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($16.65M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($9.11M)
May 15, 2024
Q3
2023
Sep 30, 2022
($6.43M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($4.10M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($22.04M)
May 11, 2023
Q3
2022
Sep 30, 2021
($7.04M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($15.21M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($16.00M)
May 13, 2022
Q3
2021
Sep 30, 2020
($7.24M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($13.01M)
Jul 28, 2021
Q1
2021
Mar 31, 2020
($48.16M)
May 17, 2021
Q2
2020
Mar 31, 2020
($48.16M)
Aug 10, 2020
Q3
2020
Sep 30, 2019
($17.37M)
Nov 9, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($24.02M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($22.79M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($19.73M)
May 15, 2025
Q3
2025
Sep 30, 2024
($15.35M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($17.86M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($14.33M)
May 15, 2025
Q3
2024
Sep 30, 2023
($11.33M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($10.55M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($12.04M)
May 15, 2024
Q3
2023
Sep 30, 2022
($9.38M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($8.01M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($20.59M)
May 11, 2023
Q3
2022
Sep 30, 2021
($14.87M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($13.72M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($14.60M)
May 13, 2022
Q3
2021
Sep 30, 2020
($6.25M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($12.48M)
Jul 28, 2021
Q1
2021
Mar 31, 2020
($48.21M)
May 17, 2021
Q3
2020
Sep 30, 2019
($17.65M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($23.98M)
Aug 10, 2020